Peter Ordentlich - Feb 15, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Feb 15, 2023
Transactions value $
-$1,118,394
Form type
4
Date filed
2/17/2023, 05:09 PM
Previous filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $48.3K +7.57K $6.38 7.57K Feb 15, 2023 Direct
transaction SNDX Common Stock Sale -$196K -7.57K -100% $25.84 0 Feb 15, 2023 Direct F1, F2
transaction SNDX Common Stock Options Exercise $125K +17.4K $7.20 17.4K Feb 15, 2023 Direct
transaction SNDX Common Stock Sale -$450K -17.4K -100% $25.84 0 Feb 15, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise -$450K -17.4K -100% $25.84 0 Feb 15, 2023 Common Stock 17.4K $7.20 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise -$196K -7.57K -100% $25.84 0 Feb 15, 2023 Common Stock 7.57K $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $25.53 to $26.10.
F3 This option is fully vested.